Medial EarlySign Funding: How Much Did They Raise & Key Investors

How Much Did Medial EarlySign Raise?
Funding & Key Investors

Medial EarlySign has solidified its position in the predictive healthcare sector, securing a total capital infusion of $50M. This trajectory of financial backing, punctuated by a recent strategic investment of $30M, underscores the market confidence in the company's ability to leverage machine learning for clinical outcomes. By integrating advanced data analytics into routine care, the firm continues to attract significant interest from institutional backers focused on the intersection of artificial intelligence and medical diagnostics.

The company's growth story began with its initial Series A financing in 2013, followed by a substantial Series B round in 2019. This progression reflects a mature development cycle, moving from foundational research to the large-scale deployment of its proprietary software solutions across global healthcare systems.

What is Medial EarlySign?

Medial EarlySign

Software

Healthcare Software

Medial EarlySign operates at the vanguard of digital health, specializing in the early detection and prevention of high-burden diseases. The company utilizes its proprietary AlgoMarkers—a suite of outcome-focused software solutions—to analyze existing electronic health record (EHR) data and laboratory results. By identifying subtle, early indicators of high-risk patient trajectories, the platform enables healthcare providers to intervene proactively, thereby improving patient outcomes and reducing systemic costs.

Headquartered in Tel Aviv with a significant presence in Colorado, the firm bridges the gap between complex machine learning models and actionable clinical decision support. Their approach is validated by extensive peer-reviewed research, positioning them as a critical partner for health organizations seeking to optimize patient care through data-driven insights.

How much funding has Medial EarlySign raised?

Medial EarlySign has raised a total of $50M across 2 funding rounds:

2013

Series A

$20M

2019

Series B

$30M

Series A (2013): $20M with participation from Horizon Ventures

Series B (2019): $30M, investors not publicly disclosed

Key Investors in Medial EarlySign

Horizon Ventures

A prominent venture capital firm known for its global investment strategy, focusing on disruptive technologies and high-growth sectors including healthcare and digital infrastructure.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for Medial EarlySign?

With the capital secured through its recent financing, Medial EarlySign is well-positioned to scale its AlgoMarkers platform across broader international markets. The strategic focus will likely center on expanding the clinical utility of its AI-based models to encompass a wider array of chronic conditions. As healthcare systems increasingly prioritize value-based care, the demand for predictive tools that integrate seamlessly into existing workflows is expected to accelerate. The company's ability to maintain its research-backed rigor while scaling operations will be the primary determinant of its long-term market dominance in the health tech landscape.

See full Medial EarlySign company page

See More Financial Insights